Search Results - samuel+denmeade

5 Results

Sort By:

Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs

Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...

Published: 3/13/2025 | Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Sequential Hormone Therapy to Improve Survival and Enhance Response to Immune Therapy in Men with Prostate Cancer

Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an unmet clinical need to overcome resistance to hormone...

Published: 3/14/2025 | Inventor(s): Samuel Denmeade, John Isaacs, Emmanuel Antonarakis, Sushant Kachhap, Mark Markowski

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities

Novel prodrug strategy to improve clinical use of cancer drugs

Unmet Need / Invention Novelty: Clinical translation of various has been limited due to poor solubility and toxicity for repurposed anti-cancer applications. There exists an unmet need to develop new strategies to overcome these limitations. Technical Details: Researchers at Johns Hopkins have developed a novel prodrug strategy to improve solubility...

Published: 3/14/2025 | Inventor(s): William Brennen, John Isaacs, Samuel Denmeade, Emmanuel Akinboye

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology

Human Serum Albumin-PSA proaerolysin Prodrug

UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...

Published: 3/13/2025 | Inventor(s): John Isaacs, Samuel Denmeade, William Brennen

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Prostate Specific Membrane (PSMA)-binding Peptides Useful for Targeted Therapy for Cancer

C04856: Prostate Specific Membrane (PSMA)-binding Peptides Useful for Targeted Therapy for CancerTechnical Details: Prostate-Specific Membrane Antigen (PSMA) is a glutamate carboxypeptidase II that is expressed by normal prostate epithelium and is even more highly expressed by a large proportion of prostate cancers and other tumor types. As PSMA is...

Published: 3/13/2025 | Inventor(s): Samuel Denmeade, Saurabh Aggarwal

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities